Bionis Oncology Adjuvant patented technology make use of :natural active ingredient NMPA FDA TGA pending

Our vision Most people diagnosed cancer die from starvation instead of cancer attack itself. Bionis is an affordable Oncology adjuvant which target to improve quality of life and hence life expectancy of the patient. Executive Summary SynerTechcare Australia Pty led by A/Prof Cheng Yuen Yee, University Technology Sydney has successfully extract an active ingredient from rice which is normally not available by ingesting rice directly. We tested this Ingredient In Vitro and In Vivo and find it can  help damaged digestive organ cells to recover. Our product got patent application grant from HK Productivity Council since 2023. SynerTechcare Australia Pty decided to license  Bionis Pharmaceutical Limted to manufacture and develop the active ingredient Bionis into a  Chemotherapy Adjuvant. We will go through all necessary tests  on Bionis in our own laboratory, collaborating with universities , and with independent third laboratories. Our target is finally listed the Bionis  with TGA. One of the hardest standard for Pharmaceutical products.  We plan to have these done with in 4 years. For raw material, our affiliated will collect it for us. For manufacturing we have GMP approved Manufacture in Australia. We are looking for partners inning Kong Science park to pack and bottle the products for us. For marketing, we will leverage on our affiliated and collaborate with Pharmaceutical brands.